E. E. Just Award Lecture by Garcia, J. Victor
Volume 24 November 1, 2013 3275 
E. E. Just Award Lecture
J. Victor Garcia
Division of Infectious Diseases, Department of Medicine, Center for AIDS Research, University of North Carolina 
School of Medicine, Chapel Hill, NC 27599
ABSTRACT What started as a game of discovery for a child with a chemistry set has resulted 
in a lifetime of fulfillment and dedication to science. It is deeply rewarding to continuously let 
my curiosity ask questions for which there are no known answers. Equally rewarding has been 
the opportunity to mentor young students and postdoctorate graduates through their for-
mative years in science.
When I was a child growing up, my parents had an orchard. In the 
orchard, they cultivated oranges. But my father expanded his one-
man operation to other crops including corn, 
peppers, and tomatoes. At our house, we 
also had several fruit trees. At nights in the 
summer, I would be awakened by hard thumps 
on the tin roof of the building where we 
parked vehicles and farm equipment. These 
sounds indicated that either a mango or an 
avocado had fallen from a tree. Early in the 
morning, I would climb up on the roof and 
collect as many of them as I could. Then I 
would set up a small stall by the door to our 
house and sell my goods to passersby. When 
the corn was in and had dried, it would take 
hours to shell by hand, but it brought a great 
price. So what did I do with all the money I 
made? I bought the most amazing chemistry 
set! It was like magic to me. That was it for 
me. I was hooked. Even though neither of my 
parents had a formal education beyond sec-
ondary school, and no one in my family at that 
time had gone to a university, I wanted to be a scientist. My father 
worked three jobs to take care of my six siblings, my mother, and 
me. It was a great sacrifice to send me to college. When I first 
arrived there, I did not do so well. It took me a while to academically 
catch up with my peers, but eventually I did. The most important 
lesson I learned in college was to have a good 
work/study ethic. The second was chemistry. 
While I was in college, my dad died in a tragic 
automobile accident that killed two men and 
left 14 children without a father. My mother 
took over raising and financially supporting 
my siblings and me, and she set for us a very 
high example of success. Even though she 
did not have a formal high school or college 
education, she gave us all an education and 
then helped all of us to obtain postgraduate 
education. After completing this monumental 
task, and 10 grandchildren later, she ran and 
was elected to Congress. Did I say she has 
been a hard act to follow? She is my source of 
inspiration.
As an aspiring student of science, I was 
very fortunate to have outstanding mentors. 
By the time I arrived at graduate school, I was 
well prepared for the rigors of the lab. I earned 
a PhD in chemistry with a focus on nucleic acid/protein interactions 
in a tremendously rigorous program that provided me with the type 
of fundamental quantitative skills that have served me well the rest 
of my academic life. Even courses like molecular dynamics have pro-
vided me with the type of broad scientific base that is needed to 
work in a highly competitive discipline.
If there is one piece of advice I would give to anyone interested 
in a career in science, or in any other field for that matter, it would 
be: be flexible. Let everything around you guide you in whatever is 
your quest. Don’t think the answer you thought up is the correct 
one. It might be. Yet it might not always be the only one or the com-
plete story. Many years ago, I heard someone say, “the truth is some-
where in the middle.” How can that be in science? Science is about 
precision. Absolutes. Certainty. Proof. Then I was told that I was 
“more interested in the middle than the truth.” In other words, many 
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According to estimates by the World Health Organization (WHO) 
and the Joint United Nations Program on HIV/AIDS, 34 million peo-
ple were living with HIV at the end of 2011. That same year, some 
2.5 million people became newly infected, and 1.7 million died of 
AIDS-related causes, including 230,000 children. BLT mice have 
opened numerous new lines of investigation that were not possible 
even a few years ago. In addition, they have contributed to our de-
tail understanding of the complex interactions between pathogen 
and host. The first highly significant contribution using the BLT 
model was to our understanding of mucosal HIV transmission (Sun 
et al., 2007). Specifically, in developed countries like the United 
States, the vast majority of transmission events occur during unpro-
tected anal intercourse. We therefore investigated the reconstitu-
tion with human lymphoid cells of the gastrointestinal tract of BLT 
mice. Our result showed that the gastrointestinal tract of BLT mice 
closely resembles that of humans and, in addition, that these mice 
(like humans), if exposed rectally, can be infected by HIV. In addition, 
we were able to demonstrate the critical role of cryptopatches as 
the essential anlagen for the development of organized immune 
tissue in the gut (Nochi et al., 2013). Subsequently, we found that 
the entire female reproductive tract of BLT mice is reconstituted with 
human immune cells. Vaginal HIV transmission is responsible for the 
majority of new HIV infections worldwide. This prompted us to de-
termine whether human immune cells were present in the female 
reproductive tract of BLT mice. Remarkably, the presence of human 
immune cells in this tissue rendered female BLT mice susceptible to 
vaginal HIV transmission (Denton et al., 2008). We subsequently lev-
eraged the fact that BLT mice are susceptible to rectal and vaginal 
HIV transmission to evaluate a variety of different inhibitors for their 
ability to prevent HIV acquisition. The results demonstrated that 
several novel HIV inhibitors, as well as several FDA-approved HIV 
inhibitors, could efficiently block both rectal and vaginal HIV trans-
mission. Subsequently, the FDA has approved two of these agents 
for use in HIV prevention.
Despite the availability of numerous antivirals, every day, 1000 
children are newly infected with HIV. A significant number of these 
children acquire the infection via breast-feeding. Novel approaches 
to oral HIV prevention are urgently needed. In this regard, we have 
recently shown that BLT mice recapitulate key aspects of oral HIV 
transmission, and this information was used to test novel ap-
proaches to prevent infection. One unexpected but nevertheless 
very interesting outcome of these experiments was the demonstra-
tion that human breast milk has a very strong and highly reproduc-
ible innate inhibitory activity that prevents both HIV infection and 
its transmission (Wahl et al., 2012). These experiments addressed a 
paradigm in the field: If milk has an anti-HIV activity, how is it pos-
sible for infants to become infected? For this, one has to keep in 
mind that children born to HIV-infected mothers receive liters and 
liters of HIV-infected milk during their first six months of life and yet 
only ∼1/10 become infected. Thus the results obtained in the BLT 
model strongly support the protective effect of milk in preventing 
HIV transmission and have opened up new avenues of investiga-
tion addressing the nature of the innate viral inhibitors present in 
human breast milk and have provided support for the WHO’s rec-
ommendation to provide breast milk to infants of HIV-infected 
mothers.
Now our research includes a new ambitious goal: to find a cure 
for HIV/AIDS. In this regard, BLT mice have proven to be an out-
standing tool for discovery. BLT mice have been shown to establish 
the same type of HIV persistence that is observed in HIV patients 
treated with antiretroviral therapy (Denton et al., 2012). This 
provides an opportunity to use this model to evaluate novel 
so-called truths have changed, been proven wrong, developed fur-
ther, or amended. All of these new discoveries were made because 
someone did not accept something as an incontrovertible truth. The 
development of the humanized bone marrow/liver/thymus (BLT) 
mouse model is a prime example of this (Melkus et al., 2006).
Our laboratory had been developing gene transfer vectors based 
on the human immunodeficiency virus (HIV) (now called “lenti” vec-
tors; Douglas et al., 1999). We had great success in using these vec-
tors to transduce human hematopoietic stem cells in vitro but did not 
have a way to establish whether or not this could be translated into 
future clinical applications, as we lacked suitable in vivo animal mod-
els. We set up a human hematopoietic stem cell transplantation 
model in which we could demonstrate the capacity of these vectors 
to efficiently transduce these cells, resulting in multilineage reconsti-
tution with human immune cells. Even though this approach was 
highly successful, and we were able to demonstrate the presence of 
transduced B-cells, monocytes, macrophages, dendritic cells, and so 
on, we were not able to detect any human T-cells in these animals 
(Gatlin et al., 2001). This was a problem because we wanted to de-
velop gene therapy for AIDS, and T-cells are a key cell type during 
the course of HIV infection. We were aware of another in vivo model 
in which human thymic/liver tissue implanted in a different type of 
immunodeficient mouse developed into a well-defined human thy-
mus–like organ. These thymic “organoids” produced human thymo-
cytes and could be infected with HIV. Unfortunately, these thymo-
cytes did not exit the organoid, and there was no peripheral 
reconstitution with human T-cells, which severely limited the use of 
this model. Interestingly, in contrast with the transplant model de-
scribed above, in this tissue implant model there were no other type 
of human immune cells present, only thymocytes. We decided to test 
whether these two systems could be combined into one that would 
have a complete human hematopoietic system. When the student 
who was carrying out these experiments discussed his project with 
the “experts,” he was told that his approach had been extensively 
tested and that it had failed in all its previous interactions. He was 
utterly distressed about all the negativity we encountered from col-
leagues and grant reviewers. However, I reminded him that we had 
one ace in the hole. What we had noted was the fact that, whereas all 
tissue implants were done with one specific strain of mice, all he-
matopoietic stem cell transplants were performed in a different strain 
of mice. The strain of mice used for tissue implants was not used for 
transplants, because of resulting low engraftment levels. The strain of 
mice used for transplants was not used for implants, because those 
mice had a shorter life span. When we implanted one small piece of 
human liver tissue sandwiched between two small pieces of thymic 
tissue into the mice that could be efficiently transplanted with autolo-
gous human hematopoietic stem cells, the results of this combina-
tion approach were dramatic. In essence, the animals developed a 
bona fide human thymic organoid, and, in addition to a full comple-
ment of T-cells, they also developed virtually all other bone marrow–
derived human hematopoietic cells (Melkus et al., 2006). In short, we 
had created a chimeric human/mouse model that had a functioning 
systemic human immune system. These animals were designated 
bone marrow/liver/thymus mice, because they are the results of a 
bone marrow transplant with autologous CD34+ hematopoietic stem 
cells of animals coimplanted with liver and thymic tissue. Since then, 
the name has been shortened to BLT.
Since our original description of this model, BLT mice have been 
extensively used to study numerous aspects of human immunology, 
hematopoiesis, cell biology, microbiology, and so on. However, the 
area in which BLT mice have made their most significant contribu-
tion is HIV and AIDS research.
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approaches aimed at eradicating HIV from infected patients. 
Whether or not the observations made in BLT humanized mice can 
eventually be translated into human clinical applications has yet to 
be determined. Nevertheless, to date, the information obtained 
from experiments using BLT mice has been demonstrated to be 
highly relevant when making evidence-based decisions concern-
ing which novel approaches have the best chance of success when 
implemented in humans and should be given priority in develop-
ment pipelines.
What started as a game of discovery for a child with a chemistry 
set has resulted in a lifetime of fulfillment and dedication to sci-
ence. It is deeply rewarding to continuously let my curiosity ask 
questions for which there are no known answers. Equally rewarding 
has been the opportunity to mentor young students and postdoc-
torate graduates through their formative years in science. Their cu-
riosity and dedication inspires me, and I have learned from them as 
much, if not more, than I have taught. I look toward the future with 
the hope that together we will continue to contribute to the ad-
vancement of science in general and ultimately find a cure for HIV/
AIDS. For each one of my students and trainees, I have one wish: 
that they will surpass anything in science that I have accomplished 
during my lifetime.
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